This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (79)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Neurology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Meta-analysis and Hypotheses

Robert G. Hart, MD; Jonathan L. Halperin, MD; Ruth McBride, BS; Oscar Benavente, MD; Malcolm Man-Son-Hing, MD; Richard A. Kronmal, PhD

Arch Neurol. 2000;57:326-332.

Background  Aspirin therapy reduces stroke by about 25% for persons with atherosclerotic vascular disease, but the effect in those without clinically apparent vascular disease is distinctly different.

Objective  To define the effect of aspirin use on stroke and other major vascular events when given for primary prevention to persons without clinically recognized vascular disease.

Data Sources and Extraction  Systematic review of randomized clinical trials and large prospective observational cohort studies examining the relation between aspirin use and stroke in persons at low intrinsic risk. Studies were identified by a computerized search of the English-language literature.

Data Synthesis  Five randomized trials of primary prevention included 52,251 participants randomized to aspirin doses ranging from 75 to 650 mg/d; the mean overall stroke rate was 0.3% per year during an average follow-up of 4.6 years. Meta-analysis revealed no significant effect on stroke (relative risk = 1.08; 95% confidence interval, 0.95-1.24) contrasting with a decrease in myocardial infarction (relative risk = 0.74; 95% confidence interval, 0.68-0.82). The lack of reduction of stroke by aspirin for primary prevention was incompatible with its protective effect against stroke in patients with manifest vascular disease (P = .001). Intracranial hemorrhage was increased by the regular use of aspirin (relative risk = 1.35; P = .03), similarly for both primary and secondary prevention. In 4 large observational studies, self-selected use of aspirin was consistently associated with higher rates of stroke.

Conclusions  The effect of aspirin therapy on stroke differs between individuals based on the presence or absence of overt vascular disease, in contrast with the consistent reduction in myocardial infarction by aspirin therapy observed in all populations. We hypothesize that the effect of aspirin therapy on stroke for persons with major risk factors for vascular disease may be intermediate between a substantial decrease for those with manifest vascular disease and a possible small increase for healthy persons due to accentuated intracranial hemorrhage. When aspirin is given for primary prevention of vascular events, available data support using 75 to 81 mg/d.

From the Department of Medicine (Neurology), University of Texas Health Science Center, San Antonio (Drs Hart and Benavente); The Cardiovascular Institute, Mount Sinai Medical Center, New York, NY (Dr Halperin); Statistics Epidemiology Research Corporation, Seattle, Wash (Ms McBride); Division of Geriatric Medicine, University of Ottawa, Ottawa, Ontario (Dr Man-Son-Hing); and the Department of Biostatistics, University of Washington, Seattle (Dr Kronmal).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Aspirin Benefit Remains Elusive in Primary Stroke Prevention
H. J. M. Barnett and Michael Eliasziw
Arch Neurol. 2000;57(3):306-308.
EXTRACT | FULL TEXT  

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2000;57(3):430-432.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Aspirin for primary prevention of cardiovascular disease?
DTB 2009;47:122-125.
ABSTRACT | FULL TEXT  

Beneficial effects of 1-year optimal medical treatment with and without additional PTA on inflammatory markers of atherosclerosis in patients with PAD. Results from the Oslo Balloon Angioplasty versus Conservative Treatment (OBACT) study
Nylaende et al.
Vasc Med 2007;12:275-283.
ABSTRACT  

The Use of Aspirin for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force
Dube et al.
ANN INTERN MED 2007;146:365-375.
ABSTRACT | FULL TEXT  

Aspirin for the Primary Prevention of Cardiovascular Disease in Women: A Cost-Utility Analysis
Pignone et al.
Arch Intern Med 2007;167:290-295.
ABSTRACT | FULL TEXT  

Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline.
Goldstein et al.
Circulation 2006;113:e873-e923.
ABSTRACT | FULL TEXT  

Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline.
Goldstein et al.
Stroke 2006;37:1583-1633.
ABSTRACT | FULL TEXT  

Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.
Pignone et al.
ANN INTERN MED 2006;144:326-336.
ABSTRACT | FULL TEXT  

Risk of Hemorrhagic Stroke With Aspirin Use: An Update
Gorelick and Weisman
Stroke 2005;36:1801-1807.
ABSTRACT | FULL TEXT  

ASHP Therapeutic Position Statement on the Daily Use of Aspirin for Preventing Cardiovascular Events
Saseen
Am J Health Syst Pharm 2005;62:1398-1405.
FULL TEXT  

Avoiding Central Nervous System Bleeding During Antithrombotic Therapy: Recent Data and Ideas
Hart et al.
Stroke 2005;36:1588-1593.
ABSTRACT | FULL TEXT  

Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged >=70
Nelson et al.
BMJ 2005;330:1306.
ABSTRACT | FULL TEXT  

Advanced Age, Anticoagulation Intensity, and Risk for Intracranial Hemorrhage among Patients Taking Warfarin for Atrial Fibrillation
Fang et al.
ANN INTERN MED 2004;141:745-752.
ABSTRACT | FULL TEXT  

Current and future concepts in stroke prevention
O'Rourke et al.
CMAJ 2004;170:1123-1133.
ABSTRACT | FULL TEXT  

New Evidence for Stroke Prevention: Scientific Review
Straus et al.
JAMA 2002;288:1388-1395.
ABSTRACT | FULL TEXT  

Vascular disease and survival in patients with type 2 diabetes and nephropathy
Joss et al.
British Journal of Diabetes & Vascular Disease 2002;2:137-142.
ABSTRACT  

Aspirin for the Primary Prevention of Cardiovascular Events: A Summary of the Evidence for the U.S. Preventive Services Task Force
Hayden et al.
ANN INTERN MED 2002;136:161-172.
ABSTRACT | FULL TEXT  

How well is the clinical importance of study results reported? An assessment of randomized controlled trials
Chan et al.
CMAJ 2001;165:1197-1202.
ABSTRACT | FULL TEXT  

Comparison of Evidence of Treatment Effects in Randomized and Nonrandomized Studies
Ioannidis et al.
JAMA 2001;286:821-830.
ABSTRACT | FULL TEXT  

Review: aspirin lowers the risk for MI but not for stroke in people who do not have established vascular disease
Harvey
Evid. Based Med. 2000;5:174-174.
FULL TEXT  

What causes intracerebral hemorrhage during warfarin therapy?
Hart
Neurology 2000;55:907-908.
FULL TEXT  

Aspirin Ineffective in Primary Prevention of Stroke
Journal Watch Dermatology 2000;2000:14-14.
FULL TEXT  

Aspirin Ineffective in Primary Prevention of Stroke
JWatch General 2000;2000:1-1.
FULL TEXT  

Aspirin Benefit Remains Elusive in Primary Stroke Prevention
Barnett and Eliasziw
Arch Neurol 2000;57:306-308.
FULL TEXT